Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values
Authors:
- 1 January 1994
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 73 (1) , 61-64
Abstract
Objectives Prostate specific antigen (PSA) measurement has become increasingly popular as a screening test for prostatic adenocarcinoma. Although this is a sensitive, organ‐specific assay, use as a screening tool is hampered by the lack of a clearly defined normal range in older men, frequent elevation of PSA levels by benign processes, and the availability of two different assays, one polyclonal and the other monoclonal, which produce very different values. This study was designed to evaluate the distribution of PSA levels by the Yang and corresponding Hybritech values in patients from the general population. Subjects and methods A total of 478 volunteers over 40 years of age underwent serum PSA determination by the Yang polyclonal radioimmunoassay and digital rectal examination. The PSA levels were stratified and the patient distribution analysed. Results In 69% of patients, PSA levels were ≤ 2.5 ng/ml (proposed normal range for the Yang polyclonal assay). In 89% of patients, PSA levels were ≤ 7.3 ng/ml by the polyclonal assay which corresponds approximately to the proposed normal range of 0–4.0 ng/ml by the Hybritech monoclonal assay. Nine per cent of patients fell between 7.4 and 18.4 ng/ml by the polyclonal assay (4.1–10 ng/ml by the monoclonal assay) and 2% had polyclonal PSA levels > 18.4 ng/ml (> 10 ng/ml by the monoclonal assay). Cancer detection rates (influenced by the percentage of patients undergoing biopsy) were 0.3% in patients with polyclonal PSA levels ≤ 2.5 ng/ml, 1.2% in patients ≤ 7.3 ng/ml, 20.9% between 7.4 and 18.4 ng/ml, and 50% of those > 18.4 ng/ml; the overall cancer detection rate was 3.8%. Conclusions These data support the use of higher PSA levels as a criterion for further evaluation in screening for prostate cancer and establish the frequency distribution of PSA in a screening population when the Yang assay is used.Keywords
This publication has 7 references indexed in Scilit:
- Screening for Prostatic Carcinoma with Prostate Specific AntigenJournal of Urology, 1992
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Prostate Cancer: Comparison of Digital Rectal Examination and Transrectal Ultrasound for ScreeningJournal of Urology, 1991
- Comparison of a Polyclonal and Monoclonal Immunoassay for PSA: Need for an International Antigen StandardJournal of Urology, 1990
- Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific AntigenJournal of Urology, 1990
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.Clinical Chemistry, 1987